| Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population … MR Moore, R Link-Gelles, W Schaffner, R Lynfield, C Lexau, NM Bennett, ... The Lancet Infectious Diseases 15 (3), 301-309, 2015 | 756 | 2015 |
| Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak—United States, December 31, 2019–February 4, 2020 A Patel MMWR. Morbidity and mortality weekly report 69, 2020 | 477 | 2020 |
| Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites DR Feikin, EW Kagucia, JD Loo, R Link-Gelles, MA Puhan, T Cherian, ... PLoS medicine 10 (9), e1001517, 2013 | 475 | 2013 |
| Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of … MG Thompson MMWR. Morbidity and mortality weekly report 71, 2022 | 403 | 2022 |
| Characteristics associated with hospitalization among patients with COVID-19—Metropolitan Atlanta, Georgia, March–April 2020 ME Killerby, R Link-Gelles, SC Haight, CA Schrodt, L England, DJ Gomes, ... Morbidity and mortality weekly report 69 (25), 790, 2020 | 391 | 2020 |
| Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during … JM Ferdinands, S Rao, BE Dixon, PK Mitchell, MB DeSilva, SA Irving, ... Morbidity and Mortality Weekly Report 71 (7), 255, 2022 | 376 | 2022 |
| Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States Nature medicine 26 (6), 861-868, 2020 | 322 | 2020 |
| Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 … S Nanduri, T Pilishvili, G Derado, MM Soe, P Dollard, H Wu, Q Li, ... Morbidity and Mortality Weekly Report 70 (34), 1163, 2021 | 312 | 2021 |
| National update on measles cases and outbreaks—United States, January 1–October 1, 2019 M Patel, AD Lee, NS Clemmons, SB Redd, S Poser, D Blog, JR Zucker, ... Morbidity and Mortality Weekly Report 68 (40), 893, 2019 | 188 | 2019 |
| Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study MR Moore, R Link-Gelles, W Schaffner, R Lynfield, C Holtzman, ... The Lancet Respiratory Medicine 4 (5), 399-406, 2016 | 177 | 2016 |
| Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant S Schillie, A Harris, R Link-Gelles, J Romero, J Ward, N Nelson Morbidity and Mortality Weekly Report 67 (15), 455, 2018 | 169 | 2018 |
| Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19–associated emergency department and urgent care encounters and hospitalizations among … NP Klein, MS Stockwell, M Demarco, M Gaglani, AB Kharbanda, SA Irving, ... Morbidity and Mortality Weekly Report 71 (9), 352, 2022 | 154 | 2022 |
| Infection control assessment of ambulatory surgical centers MK Schaefer, M Jhung, M Dahl, S Schillie, C Simpson, E Llata, ... Jama 303 (22), 2273-2279, 2010 | 153 | 2010 |
| Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event T Golubchik, AB Brueggemann, T Street, RE Gertz Jr, CCA Spencer, T Ho, ... Nature genetics 44 (3), 352-355, 2012 | 129 | 2012 |
| Early COVID-19 first-dose vaccination coverage among residents and staff members of skilled nursing facilities participating in the pharmacy partnership for long-term care … R Gharpure, A Guo, CK Bishnoi, U Patel, D Gifford, A Tippins, A Jaffe, ... Morbidity and Mortality Weekly Report 70 (5), 178, 2021 | 126 | 2021 |
| Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance KE Fleming-Dutra, A Britton, N Shang, G Derado, R Link-Gelles, ... Jama 327 (22), 2210-2219, 2022 | 113 | 2022 |
| Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection—increasing community access to testing program, United States, September–November 2022 R Link-Gelles MMWR. Morbidity and Mortality Weekly Report 71, 2022 | 111 | 2022 |
| First 12 patients with coronavirus disease 2019 (COVID-19) in the United States COVID-19 Investigation Team, SA Kujawski, KK Wong, JP Collins, ... MedRxiv, 2020.03. 09.20032896, 2020 | 109 | 2020 |
| Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children RD Muhammad, R Oza-Frank, E Zell, R Link-Gelles, KMV Narayan, ... Clinical Infectious Diseases 56 (5), e59-e67, 2013 | 105 | 2013 |
| Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA. 1 and BA. 2/BA. 2.12. 1 sublineages … R Link-Gelles, ME Levy, M Gaglani, SA Irving, M Stockwell, K Dascomb, ... Morbidity and Mortality Weekly Report 71 (29), 931, 2022 | 91 | 2022 |
Amanda PayneVerified email at cdc.gov
Amanda PayneVerified email at cdc.gov